StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) company profile

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3029% above fair value
$60.97−2.52 (-3.97%)

Close on Nov 16, 2026Market cap $5.09BP/E –Yield –

About PTC Therapeutics

Pharmaceutical Preparations, SIC 2834

PTC Therapeutics is a global biopharmaceutical enterprise focused on discovering, developing, and commercializing therapies for children and adults living with rare disorders. Its operations center on treatments for neurological and metabolic conditions, featuring a commercial portfolio that includes Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza and Kebilidi for AADC deficiency. It also commercializes Tegsedi and Waylivra in specific regions and partners on Evrysdi for spinal muscular atrophy. The company serves pediatric and adult patients who have unmet medical needs.

The company maintains an international commercial footprint, supplying therapies across various global markets. Its treatments hold regulatory approvals or marketing authorizations across the United States, the European Economic Area, the United Kingdom, Japan, Brazil, Latin America, the Caribbean, and more than 100 countries globally. In addition to commercial assets, it advances a diversified development pipeline spanning splicing and inflammation platforms. The provided text does not disclose the location of its headquarters.

Summary of the business section of PTC Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
PTC Therapeutics, Inc.
Founded
1998
Headquarters
Warren, NJ
Address
500 Warren Corporate Center Drive 07059
Phone
(908) 222-7000
Employees
991, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
PTCT
Exchange
Nasdaq
IPO date
Jun 20, 2013
Shares outstanding
84M, Oct 27, 2026
Public float
$3.35M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1070081
CUSIP
69366J200
ISIN
US69366J2006
FIGI
BBG000QT15P7
Share class FIGI
BBG001SNNC86
LEI
549300UJLWOIWFDGB318
EIN
04-3416587

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Matthew B. KleinCHIEF EXECUTIVE OFFICER, Director383,868
Mark Elliott BouldingEXEC. VP AND CLO105,272
Pierre GravierCHIEF FINANCIAL OFFICER83,986
Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER65,662
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER70,199
Eric PauwelsCHIEF BUSINESS OFFICER90,977
Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER79,115
Michael SchmertzlerDirector1,454,860
Glenn Jr Md Steele PhdDirector22,500
Hege Elisabeth Sollie-ZetlmayerDirector46,526
Mary L. SmithDirector21,813
Jessica Caroline ChutterDirector7,333
Stephanie OkeyDirector8,000
Jerome B. ZeldisDirector22,500
David P. SouthwellDirector22,500
Emma ReeveDirector10,666
Alethia YoungDirector21,067
Allan Steven JacobsonDirector21,451

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$23.27M$41.16M$3.39M$125$120
FY2024$7.41M$14.73M$2.30M$74$91
FY2023
Matthew Klein
$8.94M$4.77M$2.40M$45$92
FY2023
Stuart Peltz
$5.66M-$3.54M$2.40M$45$92
FY2022$7.16M$5.40M$3.37M$63$89
FY2021$11.02M-$4.95M$4.33M$65$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Matthew B. Klein
Chief Executive Officer
$958.50K$16.59M$4.40M$1.29M$20.27K$23.27M+214%
Pierre Gravier
Chief Financial Officer
$579.17K$1.05M$1.41M$488.60K$21.66K$3.55M+59%
Eric Pauwels
Chief Business Officer
$613.15K$1.02M$1.38M$517.80K$25.36K$3.56M+49%
Lee Golden
Executive Vice President and Chief Medical Officer
$574.67K$930.80K$1.26M$482.80K$23.84K$3.27M+45%
Neil Almstead
Chief Technical Operations Officer
$582.50K$884.26K$1.19M$467.40K$30.67K$3.16M+36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 20, 2013
Offer price
$15.00
Securities offered
8,372,000
Gross proceeds
$125.58M
Exchange
Nasdaq
First trading day
Jun 20, 2013
First-day close
$16.49+9.9%
Lock-up ends (est.)
Dec 17, 2013

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 991 employees and 56 consultants and contractors.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?